Burak William E, Agnese Doreen M, Povoski Stephen P, Yanssens Tamara L, Bloom Kenneth J, Wakely Paul E, Spigos Dimitrios G
Department of Surgical Oncology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Medical Center, Columbus, Ohio 43210, USA.
Cancer. 2003 Oct 1;98(7):1369-76. doi: 10.1002/cncr.11642.
Radiofrequency ablation (RFA) is gaining acceptance as a treatment modality for several tumor types. However, its use in patients with breast carcinoma remains investigational. The current study was undertaken to determine the feasibility of treating small breast malignancies with RFA and to evaluate the postablation magnetic resonance imaging scans (MRI) and histologic findings.
Patients with core-needle biopsy-proven invasive carcinoma (< 2 cm in greatest dimension) underwent ultrasound-guided RFA under local anesthesia. Surgical excision was undertaken 1-3 weeks later. All patients had breast MRI scans performed before ablation and repeated within 24 hours of surgery.
Ten patients completed the treatment and experienced minimal or no discomfort. The mean tumor size was 1.2 cm (range, 0.8-1.6 cm). The mean time required for ablation was 13.8 minutes (range, 7-21 minutes). There were no treatment-related complications other than minimal breast ecchymosis. A pre-RFA MRI scan showed enhancing tumors in 9 of 10 (90%) patients. A post-RFA MRI scan revealed no residual lesion enhancement in 8 of these 9 patients (89%), and the zone of ablation was demonstrated in all patients. One patient had residual enhancement anteriorly consistent with residual tumor, which was confirmed histologically. Evaluation of the remaining ablated lesions revealed a spectrum of changes ranging from no residual tumor to coagulation necrosis with recognizable malignant cells. Immunostains for cytokeratin 8/18 were negative in these recognizable malignant cells.
RFA of small breast malignancies can be performed under local anesthesia in an office-based setting. A postablation MRI scan appears to predict histologic findings, although tumor viability needs to be assessed in a long-term study.
射频消融(RFA)作为多种肿瘤类型的一种治疗方式正逐渐被接受。然而,其在乳腺癌患者中的应用仍处于研究阶段。本研究旨在确定RFA治疗小乳腺癌的可行性,并评估消融后磁共振成像扫描(MRI)及组织学结果。
经粗针活检证实为浸润性癌(最大直径<2 cm)的患者在局部麻醉下接受超声引导下的RFA。1至3周后进行手术切除。所有患者在消融前均进行了乳腺MRI扫描,并在手术后24小时内重复扫描。
10例患者完成了治疗,且仅有轻微不适或无不适。肿瘤平均大小为1.2 cm(范围为0.8 - 1.6 cm)。消融平均所需时间为13.8分钟(范围为7 - 21分钟)。除了轻微的乳腺瘀斑外,未发生与治疗相关的并发症。RFA前的MRI扫描显示10例患者中有9例(90%)肿瘤有强化。RFA后的MRI扫描显示这9例患者中有8例(89%)无残留病变强化,且所有患者均显示出消融区。1例患者前部有残留强化,与残留肿瘤一致,经组织学证实。对其余消融病变的评估显示了一系列变化,从无残留肿瘤到有可识别恶性细胞的凝固性坏死。这些可识别的恶性细胞中细胞角蛋白8/18免疫染色为阴性。
小乳腺癌的RFA可在门诊局部麻醉下进行。消融后的MRI扫描似乎可以预测组织学结果,不过肿瘤的存活情况需要在长期研究中进行评估。